摘要
目的:探讨经尿道等离子电切术治疗前列腺增生的临床效果和安全性。方法:选取2013年1月-2014年1月在我院就诊的前列腺增生患者64例,并将其随机分为经尿道前列腺等离子体双极电切术(PKRP)组和经尿道前列腺电切术(TURP)组,每组各32例。PKRP组患者使用经尿道前列腺等离子体双极电切术治疗,TURP组患者使用经尿道前列腺电切术治疗,术后观察和比较两组患者的临床疗效及并发症的发生情况。结果:与TURP组比较,PKRP组的手术时间显著延长,术中出血量明显减少,导尿管留置时间、住院时间均显著缩短,腺体切除量明显增加,差异具有统计学意义(P<0.05)。术后,两组的IPSS、QOL、RUV和Qmax均较术前显著改善(P<0.05),且PKRP组患者的IPSS、QOL、RUV均显著低于TURP组,而Qmax明显高于TURP组,差异具有统计学意义(P<0.05)。两组的不良反应包括前列腺电切综合征、暂时性尿失禁、迟发性出血和尿道狭窄,PKRP组的总发生率显著低于TURP组,差异具有统计学意义(P<0.05)。结论:PKRP治疗前列腺增生的临床效果优于TURP,患者恢复快,并发症发生率低,值得临床合理选用。
Objective： To explore the clinical effect of transurethral plasmakinetic resection in the treatment of benign prostatic hy- perplasia. Methods： Selected 64 cases of benign prostatic hyperplasia patients who doctored in our hospital from January 2013 to 2014, it was randomly divided into PKRP group and TURP group, 32 cases in each group. Group PKRP patients used transurethral plasmakinetic resection of prostate for treatment, patients in TURP group with transurethral resection of the prostate for treatment. Comparison of two groups patients postoperation curative effect index, and recorded the complications. Results： Compared with the TURP group, operation time of PKRP group significantly increased, the amount of bleeding significantly reduced, indwelling catheter time and hospitalization shortened significantly, gland excision increased, the differences was statistically significant （P〈0.05）. After operation, the IPSS, QOL, RUV and Qmax significantly improved when compared with before （P〈0.05）, and PKRP group was significantly lower than that of TURP group, while Qmax was higher than that in group TURP （P〈0.05）. Adverse reactions of the two groups including transurethral re- section syndrome, temporary incontinence, delayed hemorrhage and urethral stricture, the total incidence rate in PKRP group was signifi- cantly lower than that in TURP group, the difference was statistically significant （P〈0.05）. Conclusion： The clinical effect of PKRP in the treatment of benign prostatic hyperplasia is better than TURP and it is worthy of clinical rational use.
出处
《现代生物医学进展》
CAS
2015年第21期4049-4051,4090,共4页
Progress in Modern Biomedicine
基金
上海市卫生局申康医院发展中心项目资助(SHDCI2007316)
